A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 27 Nov 2017 Planned End Date changed from 31 Jul 2023 to 31 Oct 2024.
- 27 Nov 2017 Planned primary completion date changed from 31 Jul 2023 to 7 Feb 2020.
- 10 Jun 2017 Biomarkers information updated